AbbVie's SWOT analysis: stock outlook amid Humira erosion and pipeline growth
AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...
AbbVie price target lowered to $212 from $221 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...
AbbVie stock target cut, keeps Buy rating on growth outlook
Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...
Europe Pharmaceutical Drugs Market Projected To Witness Substantial Growth, 2025-2032: Astrazeneca., Baxter, Novartis AG
Europe Pharmaceutical Drugs Market Projected To Witness Substantial Growth, 2025-2032: Astrazeneca., Baxter, Novartis AG Europe pharmaceutical drugs market is estimated to be valued at US$ 180.2 Bn in ...
Investing7h
US Dollar Index (DXY)
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Morningstar21h
Federated Hermes MDT Large Cap Value A
Federated Hermes MDT Large Cap Value Fd earns an Above Average Process Pillar rating. The primary contributor to the rating is the fund's impressive long-term risk-adjusted performance. This can ...